JP2012503652A - リウマチ性関節炎、震え・パーキンソン病、多発性硬化症及び非ウィルス性の癌の治療方法 - Google Patents
リウマチ性関節炎、震え・パーキンソン病、多発性硬化症及び非ウィルス性の癌の治療方法 Download PDFInfo
- Publication number
- JP2012503652A JP2012503652A JP2011528993A JP2011528993A JP2012503652A JP 2012503652 A JP2012503652 A JP 2012503652A JP 2011528993 A JP2011528993 A JP 2011528993A JP 2011528993 A JP2011528993 A JP 2011528993A JP 2012503652 A JP2012503652 A JP 2012503652A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- preparing
- composition comprises
- administering
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 39
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 21
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 19
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 15
- 230000003612 virological effect Effects 0.000 title claims abstract description 12
- 201000011510 cancer Diseases 0.000 title claims description 14
- 206010008531 Chills Diseases 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 239000000427 antigen Substances 0.000 claims abstract description 26
- 102000036639 antigens Human genes 0.000 claims abstract description 26
- 108091007433 antigens Proteins 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 239000012190 activator Substances 0.000 claims abstract description 19
- 230000001580 bacterial effect Effects 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 230000036039 immunity Effects 0.000 claims abstract description 14
- 230000001939 inductive effect Effects 0.000 claims abstract description 14
- 208000016192 Demyelinating disease Diseases 0.000 claims abstract description 11
- 206010012305 Demyelination Diseases 0.000 claims abstract description 8
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 7
- 229940029583 inactivated polio vaccine Drugs 0.000 claims description 26
- 229960000814 tetanus toxoid Drugs 0.000 claims description 20
- 229960005486 vaccine Drugs 0.000 claims description 16
- 229940124929 TYPHIM Vi Drugs 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 11
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 5
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 5
- 206010039966 Senile dementia Diseases 0.000 claims description 5
- 241001493065 dsRNA viruses Species 0.000 claims description 5
- 229960001438 immunostimulant agent Drugs 0.000 claims description 5
- 239000003022 immunostimulating agent Substances 0.000 claims description 5
- 230000003308 immunostimulating effect Effects 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 229940124452 immunizing agent Drugs 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 34
- 206010044565 Tremor Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 230000001537 neural effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 210000000987 immune system Anatomy 0.000 description 9
- 210000004247 hand Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000006378 damage Effects 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 5
- 210000003007 myelin sheath Anatomy 0.000 description 5
- 102000006386 Myelin Proteins Human genes 0.000 description 4
- 108010083674 Myelin Proteins Proteins 0.000 description 4
- 210000005012 myelin Anatomy 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 108030001722 Tentoxilysin Proteins 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 241001467018 Typhis Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000023105 myelination Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960001266 typhoid vaccines Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010071368 Psychological trauma Diseases 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 208000025223 poliovirus infection Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/38—Antigens from snakes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明はこれらの又は他のニーズを満たすものである。
本発明のもうひとつの側面は、免疫誘発剤とバクテリア抗原活性剤の組成物を調製するステップと、その配合物を患者に投与するステップを含む、患者の痛みと炎症の治療方法を対象としている。
関連するモダリティにおいて、休止中の小児期感染が、潜在状態であったがん性細胞の複製を誘発する基礎を形成することもある。
したがって、適切なワクチン治療をすれば、この作用に対抗できるはずであり、本発明の組成物は免疫誘発剤を含む。
適切な免疫誘発剤とは、脱髄疾患の患者に対患しある程度の免疫を与える能力をもつ、ワクチンのような製剤である。好ましくは、当該疾患は患者の中枢神経系(「CNS」)を貫通する能力を持つことが知られている。
また、この組成物の投与のステップは、この組成物70ccを皮下注射することを含む。
1.RAは61歳の男性で過去10年間両手、指、背中にリウマチ性関節炎を患ってきた。5年前に薬剤治療を始め、薬剤服用後1時間以内に、両手、指、背中の痛みが消え、第二の薬剤で痛みもなく、動きも何も不自由がなくなった。彼は現在基本的に関節炎の症状から解放され、毎週その治療薬服用を継続している。副作用は全く無い。
2.RAは、リウマチ性関節炎のためにゴルフを断念した63歳の女性である。関節炎は両手、また手首にあり、背中にも10年間症状があったと自覚している。2年前に薬剤治療を始め、薬剤服用後45分以内で基本的に痛みが解消し、手首、両手に全く完全な動きが認められ、背中にも全く痛みが消え失せた。彼女は5日ごとに一回その治療薬を服用し、継続的に痛みから開放されている。副作用は全く無い。
3.RAは82歳の男性で、20年間重度のリウマチ性関節炎を患ってきた。彼の両手は過去20年間拳骨を握り締めた状態で、両手に甚大な痛みを覚えていた。彼は3年前に最初の投薬を受けた。服用後45分後には彼は20年間の痛みが消え喜びに涙し、投薬後1時間半後には両手を1インチ(2.54cm)開くことができた。彼は5日置きに治療を続け、両手の動きを完全に取り戻し、苦痛も副作用も全く無い。
1.MSは62歳の、進行した多発性硬化症を患う女性である。8年間彼女は右足の甚大な痛みに苦しみ、車椅子生活を強いられ、失禁、赤痢、複数の脳せん断を経験していた(彼女の主治医はこのように多数の脳せん断を示した患者を見たのは死骸のものだったと言う)。彼女は2年半前に薬剤治療を始めた。最初の薬剤では痛みが50%解消し、2日後の第二回薬剤投与では、45分以内で痛みは全く認められなくなった。4日後の第3回の薬剤治療では、彼女は依然として痛みがなく、立ち上がり、ウォーカーを用いて歩き回ることができた。4日後の第4回目の薬剤治療では、依然として痛み、失禁、赤痢の微侯もなく、副作用もなかった。5日おきに薬剤の服用を開始し、健康的な痛みの無い生活を維持し、現在も赤痢や副作用は全く無い。
1.Pは64歳の男性で1年前に左手にかすかな震えを時折感じていた。自分では神経的なものだろうと思っていたが、時が経つにつれ震えは頻度を増した。医者の診断を受けたところ、神経的なものか、あるいはパーキンソン病の初期かもしれないが、剖検しない限り(オプションではない)断定できないと告げられた。彼は複合ビタミン剤を試したが効果はなかった。最初の治療薬投与後、震えは45分以内に止まり、副作用は認められなかった。1週間後、左手に動きが現れ、もう一度投与すると動き・震えは止まった。以来彼は週ごとに投与を受け、何の震えも副作用も認められていない。
12年前、PはPSAスコア68、グリソン(Gleason)スコア7であった。前立腺全摘出術を実施し、術後の診断でPは1〜2年の追加余命が与えられた。本発明のワクチンを投与開始後、PのPSAスコアは−0.03でそのまま12年生存している。
また、この組成物の投与のステップは、この組成物0.70ccを皮下注射することを含む。
Claims (28)
- 免疫誘発剤とバクテリア抗原活性剤を含む組成物。
- 免疫誘発剤が一本鎖のRNAウィルスのワクチンを含む請求項1記載の組成物。
- 免疫誘発剤が不活性化したポリオワクチンを含む請求項2記載の組成物。
- 少なくとも一つのバクテリア抗原活性剤が、破傷風トキソイドとtyphim Viを含む群から選択される請求項1記載の組成物。
- バクテリア抗原活性剤が破傷風トキソイドとtyphim Viを含む群から選択される請求項3記載の組成物。
- さらに、バクテリア抗原活性剤2部に対し不活性化ポリオワクチン5部を含む請求項5記載の組成物。
- さらに、破傷風トキソイド1部とtyphim Vi1部に対して不活性化ポリオワクチン5部を含む請求項5記載の組成物。
- 皮下注射の調合用に組成配合される請求項1記載の組成物。
- 患者の痛みと炎症を治療する方法であって、免疫誘発剤とバクテリア抗原活性剤の組成物を調製するステップ、及び
患者にその組成物を投与するステップを含む、上記方法。 - 組成物の調製のステップが、一本鎖RNAウィルスのワクチンを免疫性誘発剤に用いることを含む請求項9記載の方法。
- 組成物の調製のステップが、不活性化ポリオワクチンを免疫性誘発剤に用いることを含む請求項10記載の方法。
- 組成物の調製のステップが、破傷風トキソイドとtyphim Viを含む群から選択された、少なくとも一つのバクテリア抗原活性剤を用いることを含む請求項11記載の方法。
- 組成物の調製のステップが、バクテリア抗原活性剤2部に対し不活性化ポリオワクチン5部を使用することを含む請求項12記載の方法。
- 組成物の調製のステップが、破傷風トキソイド1部とtyphim Vi1部に対し不活性化ポリオワクチン5部を用いることを含む請求項12記載の方法。
- 組成物を投与するステップが、組成物を皮下投与することを含む請求項9記載の方法。
- 組成物を投与するステップが、約70mLの組成物を投与することを含む請求項15記載の方法。
- 患者が脱髄で特徴付けられる疾病を患っている場合の請求項9記載の方法。
- リウマチ性関節炎、多発性硬化症、アルツハイマー病、ALS(筋萎縮側索硬化症)、ギラン・バレー症候群、アテローム性動脈硬化症、統合失調症、パーキンソン病、老年性認知症からなる群から選択される請求項17記載の方法。
- 非ウィルス性癌の治療方法であって、免疫性誘発剤とバクテリア抗原活性剤の組成物を調製するステップ、及び
該配合物を患者に投与するステップを含む、上記方法。 - 組成物を調製するステップが、免疫性誘発剤のために一本鎖RNAウィルス用ワクチンを用いることを含む請求項19記載の方法。
- 組成物を調製するステップが、免疫性誘発剤のための不活性化ポリオワクチンを用いることを含む請求項20記載の方法。
- 組成物を調製するステップが、破傷風トキソイドとtyphim Viを含む群から選択した少なくとも一つのバクテリア抗原活性剤を用いることを含む請求項21記載の方法。
- 組成物を調製するステップが、バクテリア抗原活性剤2部に対し不活性化ポリオワクチンを5部を用いることを含む請求項22記載の方法。
- 組成物を調製するステップが、破傷風トキソイド1部とtyphim Vi1部に対し不活性化ポリオワクチン5部を用いることを含む請求項22記載の方法。
- 組成物を投与するステップが、組成物を皮下投与することを含む、請求項19記載の方法。
- 組成物を投与するステップが、約70mLの組成物を投与することを含む請求項25記載の方法。
- 患者が、一本鎖の線状ウィルスにより特徴付けられる潜在感染病によって誘発されたがん細胞複製によって特徴付けられる疾病を患っている、請求項19記載の方法。
- 疾病が、前立腺がん、脳癌、肺がん、乳がん、及び膵臓がんからなる群から選択される、請求項27記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2008/011233 WO2010036226A1 (en) | 2008-09-26 | 2008-09-26 | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis |
USPCT/US2008/011233 | 2008-09-26 | ||
PCT/US2008/011775 WO2010036230A1 (en) | 2008-09-26 | 2008-10-14 | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2012503652A true JP2012503652A (ja) | 2012-02-09 |
Family
ID=42059975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011528993A Pending JP2012503652A (ja) | 2008-09-26 | 2008-10-14 | リウマチ性関節炎、震え・パーキンソン病、多発性硬化症及び非ウィルス性の癌の治療方法 |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP2334325B1 (ja) |
JP (1) | JP2012503652A (ja) |
KR (1) | KR20110079816A (ja) |
CN (1) | CN102264384A (ja) |
AU (1) | AU2008362160A1 (ja) |
BR (1) | BRPI0823113A2 (ja) |
CA (1) | CA2775062A1 (ja) |
DK (1) | DK2334325T3 (ja) |
ES (1) | ES2622863T3 (ja) |
IL (1) | IL211957A0 (ja) |
MA (1) | MA32730B1 (ja) |
NZ (1) | NZ592481A (ja) |
RU (1) | RU2011118869A (ja) |
WO (2) | WO2010036226A1 (ja) |
ZA (1) | ZA201103070B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
US20100330117A1 (en) * | 2008-09-26 | 2010-12-30 | Salubrious Pharmaceutical, Llc | Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis, non-viral based cancers, alzheimers's disease, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis, west nile virus, fibromyalgia, shingles, gout, migraine headaches, senile dementia, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c |
US9877981B2 (en) | 2012-10-09 | 2018-01-30 | President And Fellows Of Harvard College | NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
US20160287621A1 (en) * | 2013-11-06 | 2016-10-06 | President And Fellows Of Harvard College | Biological production of nad precursors and analogs |
PL3204494T3 (pl) * | 2014-10-07 | 2020-09-21 | Serum Institute Of India Private Limited | Ulepszone metody inaktywacji wirusa polio i adsorpcji na adiuwancie |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10500990A (ja) * | 1994-06-02 | 1998-01-27 | クワドラント・ホールデイングス・ケンブリツジ・リミテツド | 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物 |
JP2002514398A (ja) * | 1998-05-13 | 2002-05-21 | ユニバーシティ オブ メリーランド, ボルチモア | Vi抗原を構成的に発現するSalmonellaの弱毒化した変異株 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030157129A1 (en) * | 1995-06-23 | 2003-08-21 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
WO2001025254A2 (en) | 1999-10-04 | 2001-04-12 | University Of Maryland Biotechnology Institute | Novel adjuvant comprising a lipopolysaccharide antagonist |
SE0301109D0 (sv) * | 2003-04-14 | 2003-04-14 | Mallen Huang | Nucleotide vaccine composition |
EP1718330A4 (en) * | 2004-02-06 | 2007-12-12 | Mayo Foundation | COMPLEX POLYPEPTIDE AND ADJUVANT FOR ENHANCED VACCINES |
US20060045884A1 (en) * | 2004-08-26 | 2006-03-02 | Board Of Regents | Vaccines for autoimmune and infectious disease |
WO2007076524A2 (en) * | 2005-12-29 | 2007-07-05 | Centocor, Inc. | Human anti-il-23 antibodies, compositions, methods and uses |
CA2647812A1 (en) * | 2006-03-30 | 2007-11-08 | Cogenesys, Inc. | Fusion proteins comprising alpha fetoprotein |
JP2010516626A (ja) * | 2007-01-16 | 2010-05-20 | バイパー サイエンシズ,インコーポレイティド | ガン治療剤 |
-
2008
- 2008-09-26 WO PCT/US2008/011233 patent/WO2010036226A1/en active Application Filing
- 2008-10-14 ES ES08816736.6T patent/ES2622863T3/es active Active
- 2008-10-14 RU RU2011118869/15A patent/RU2011118869A/ru not_active Application Discontinuation
- 2008-10-14 CN CN200880132113XA patent/CN102264384A/zh active Pending
- 2008-10-14 WO PCT/US2008/011775 patent/WO2010036230A1/en active Application Filing
- 2008-10-14 KR KR1020117009409A patent/KR20110079816A/ko not_active Application Discontinuation
- 2008-10-14 EP EP08816736.6A patent/EP2334325B1/en not_active Not-in-force
- 2008-10-14 AU AU2008362160A patent/AU2008362160A1/en not_active Abandoned
- 2008-10-14 BR BRPI0823113-3A patent/BRPI0823113A2/pt not_active IP Right Cessation
- 2008-10-14 NZ NZ592481A patent/NZ592481A/xx not_active IP Right Cessation
- 2008-10-14 CA CA2775062A patent/CA2775062A1/en not_active Abandoned
- 2008-10-14 JP JP2011528993A patent/JP2012503652A/ja active Pending
- 2008-10-14 DK DK08816736.6T patent/DK2334325T3/en active
-
2011
- 2011-03-27 IL IL211957A patent/IL211957A0/en unknown
- 2011-04-26 MA MA33797A patent/MA32730B1/fr unknown
- 2011-04-26 ZA ZA2011/03070A patent/ZA201103070B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10500990A (ja) * | 1994-06-02 | 1998-01-27 | クワドラント・ホールデイングス・ケンブリツジ・リミテツド | 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物 |
JP2002514398A (ja) * | 1998-05-13 | 2002-05-21 | ユニバーシティ オブ メリーランド, ボルチモア | Vi抗原を構成的に発現するSalmonellaの弱毒化した変異株 |
Also Published As
Publication number | Publication date |
---|---|
CA2775062A1 (en) | 2010-04-01 |
NZ592481A (en) | 2012-12-21 |
RU2011118869A (ru) | 2012-11-10 |
EP2334325A1 (en) | 2011-06-22 |
AU2008362160A1 (en) | 2010-04-01 |
DK2334325T3 (en) | 2017-06-26 |
WO2010036226A1 (en) | 2010-04-01 |
ZA201103070B (en) | 2011-12-28 |
EP2334325B1 (en) | 2017-03-15 |
BRPI0823113A2 (pt) | 2015-06-16 |
MA32730B1 (fr) | 2011-10-02 |
EP2334325A4 (en) | 2015-08-12 |
WO2010036230A1 (en) | 2010-04-01 |
KR20110079816A (ko) | 2011-07-08 |
CN102264384A (zh) | 2011-11-30 |
ES2622863T3 (es) | 2017-07-07 |
IL211957A0 (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012503652A (ja) | リウマチ性関節炎、震え・パーキンソン病、多発性硬化症及び非ウィルス性の癌の治療方法 | |
WO2021023264A1 (zh) | 用于治疗非洲猪瘟的药物组合物及其用途 | |
US20110020392A1 (en) | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers | |
US20190184005A1 (en) | Method and composition for ameliorating and abating symptoms resulting from rheumatoid arthritis, fibromyalgia, and chronic pain of unknown origin | |
CN101518549A (zh) | 分枝杆菌提取物的研究和应用 | |
WO2014200345A1 (en) | Method for antigen-specific tolerance induction in humans using the small heat shock protein alpha b-crystallin. | |
US20210268099A1 (en) | Method and composition for ameliorating and abating symptoms resulting from rheumatoid arthritis, fibromyalgia, and chronic pain of unknown origin | |
KR101331913B1 (ko) | 퇴행성 관절염에 대한 치료효과가 우수한 죽여 (竹茹)추출물 및 그를 포함하는 약제학적 조성물 | |
CN103908667A (zh) | 吸附无细胞百白破-Sabin株脊髓灰质炎联合疫苗及制备方法 | |
Soni et al. | Swarna Bhasma: A Hypothetical Approach to Fight against Corona Virus | |
Chen et al. | The pathology of poliomyelitis and the vaccines and nonvaccine therapy | |
Moodley et al. | Infectious or acquired motor neuron diseases | |
Shaikh et al. | POLIO AN OVERVIEW | |
KR100650451B1 (ko) | 아토피성 피부염에 치료효과를 갖는 약독화된 살모넬라균주 | |
Singh et al. | Polio: a review | |
JP2018057322A (ja) | 百日咳モデル動物およびその作製方法、ならびに百日咳モデル動物を用いた方法 | |
WO2018121499A1 (zh) | 抗结核分枝杆菌(Mycobacterium tuberculosis)及其感染的药物及其应用 | |
TW202416945A (zh) | 用於治療發炎之組合療法 | |
Mirza et al. | Dermatological side effects to certain vaccines | |
RU2226393C2 (ru) | Способ лечения иксодового клещевого боррелиоза у детей | |
CN116440111A (zh) | 左甲状腺素钠在制备预防或治疗肝损伤药物中的应用 | |
CN111249454A (zh) | 灭活卡介苗在预防或治疗新冠病毒相关病况中的用途 | |
Roy et al. | 1 Characteristics, Symptoms, Consequences and Machineries of COVID-19 and its Antidotes | |
JP2001039883A (ja) | 潰瘍性大腸炎の予防・治療用製剤ならびにその予防・治療方法 | |
Clark | Oral immunotherapy efiective in desensitizing peanut allergy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130510 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130812 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130819 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130910 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130918 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131010 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131018 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140121 |